First MDL trial over testosterone replacement drugs set for June

posted on:
May 5, 2017

author:
Matthew Teague

matt teague First MDL trial over testosterone replacement drugs set for JuneThousands of men have suffered negative and even life-threatening side effects after taking testosterone replacement drugs and they will soon have their day in court to question the drugs’ manufacturers. The first of eight bellwether cases in a multidistrict litigation (MDL) goes to trial in June.

Drug manufacturers have promised men with low testosterone or “Low T” that the hormone replacement drugs will reverse symptoms of the condition including low sex drive, fatigue, muscle loss and weight gain. However, many consumers allege they got more than they bargained for – to their detriment.

In 2014, a Food and Drug Administration (FDA) investigation confirmed findings from two studies linking the drugs to significantly higher risk of stroke, heart attack and death, Beasley Allen previously reported. It also found evidence that the drugs may cause dangerous blood clots in the legs, known as deep vein thrombosis, which can lead to pulmonary embolism. As a result, the FDA ordered drug manufacturers to update their safety labels to include a new warning for deep vein thrombosis blood clotting.

Later that year, according to Beasley Allen, the U.S. Judicial Panel on Multidistrict Litigation established the MDL for consumers seeking to hold drug manufacturers accountable for adverse side effects linked to testosterone replacement therapy. Righting Injustice recently reported the number of lawsuits has grown from 45 to 5,550 since the MDL was established. The MDL combines lawsuits from across the country, which will be tried before the U.S. District Court of the Northern District for Illinois.

The Jere Beasley Report explained that drugmakers must also answer for their aggressive marketing efforts and their attempts to downplay the risks of heart attacks and strokes associated with the drugs.

Slick marketing campaigns have fueled a sharp climb in “Low T” drug sales. The now $2 billion industry increased more than five-fold from 2000 to 2011, Beasley Allen reported. One pharmaceutical company, AbbVie, paid more than $20 million to 191,555 doctors from August 2013 to December 2015 to promote its testosterone replacement drug, AndroGel.

The drugs appear under other brand names including Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim and Testopel.

* * *

If you or a loved one has suffered a heart attack or stroke while taking testosterone supplements, or if someone you love has died, you can contact Matthew Teague, a lawyer in the firm’s Personal Injury and Product Liability Section at 800-898-2034 or by email at Matthew.Teague@beasleyallen.com. More information about testosterone replacement drugs or replacement therapy can be found at lowt-lawyer.com.

Sources:
Righting Injustice
Beasley Allen
Beasley Allen
Righting Injustice
Jere Beasley Report (January 2017)
Beasley Allen

Free Legal Consultation
At Beasley Allen, there is never a fee for legal services, unless we collect for you. Contact us today by filling out a brief questionnaire, or by calling our toll free number, 1-800-898-2034, for a free, no-cost no-obligation evaluation of your case.
back to top